This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alan Breier, MD
Maryland Psychiatric Research Center University of Maryland School of Medicine PO Box 21247 Baltimore, MD 21228

Judith L. Schreiber, MSW; David Pickar, MD
Bethesda, Md

Janyce Dyer, MSN
New Haven, Conn

Arch Gen Psychiatry. 1992;49(6):503.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply. —

We appreciate the careful review of our article¹ by Schwartz and colleagues. They raise several important points. First, they suggest that our patient group is most representative of neuroleptic treatmentresistant schizophrenia described by Kane et al² and that, therefore, our results are generalizable only to this rather narrow spectrum of schizophrenia. Semantic issues contribute to ambiguity regarding this point. Most of our patients were not literally "treatment-resistant" because they clearly became much more symptomatic during drug-free intervals and clearly improved once neuroleptic therapy was restarted^3,4 The cohort of treatment-resistant patients studied by Kane et al were characteristically "back-ward." chronically institutionalized patients. Patients in our sample were largely living in the community before index hospitalization at the National Institute of Mental Health and, therefore, not as ill. Perhaps the most accurate term to describe our cohort is "partially neuroleptic responsive." While we agree with Schwartz and . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?